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Abstract 
Background: Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk irrespective of 
conventional risk factors. The role of gut-liver interaction is implicated in its development. We investigated the effects 
of VSL#3® probiotic supplementation on biomarkers of cardiovascular risk and liver injury in patients with NAFLD.
Methods: A randomised, double-blinded, placebo-controlled, proof-of-concept study was undertaken. Patients 
with NAFLD were randomly allocated to take 2 sachets VSL#3® probiotic or placebo twice daily for 10 weeks. Meas-
urements of endothelial function (digital photoplethysmography, sVCAM-1 and cGMP), oxidative stress (glutathione 
ratio and LHP), inflammation (hsCRP), insulin resistance (HOMA-IR) and liver injury [transaminases, fibrosis risk score 
and acoustic structure quantification (ASQ)] were undertaken before and after intervention. Difference in baseline 
characteristics between the treatment groups was analysed using independent t-test or Mann Whitney U test for non-
parametric data. Independent t-test was used to compare the outcomes at the end of the study between the two 
treatment groups. Wilcoxon Signed Rank test was used to determine the difference in fibrosis risk scores before and 
after treatment. Spearman’s correlation was used to determine any association between cardiovascular and hepatic 
markers at baseline.
Results: Thirty-five patients completed the study (28 males and 7 females) with a mean age of 57 ± 8 years, body 
mass index of 32.6 ± 5.0 kg/m2 and a relatively short duration of NAFLD (median duration 0.3 IQR 2.0 years). No sig-
nificant difference was observed in biomarkers of cardiovascular risk and liver injury following VSL#3® supplementa-
tion. Significant correlations were noted between sVCAM-1 and hsCRP (rho = 0.392, p = 0.01), and HOMA-IR and AST 
(rho = 0.489, p < 0.01) at baseline.
Conclusions: This is the first study to evaluate the effect of VSL#3® on ASQ in patients with NAFLD. VSL#3® did not 
significantly improve markers of cardiovascular risk and liver injury in patients with NAFLD. However, the study sup-
ports an association between endothelial dysfunction and inflammation in patients with NAFLD and suggests that 
NAFLD is linked with insulin resistance.
Trial registration: ISRCTN05474560 (https:// doi. org/ 10. 1186/ ISRCT N0547 4560) Registered 9 August 2012 (retrospec-
tively registered).
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Background
Non-alcoholic fatty liver disease (NAFLD) is com-
monly encountered with an estimated prevalence of 
20–30% in Western countries [1] and 6–35% worldwide 
[2]. There is a strong relationship between NAFLD and 
insulin resistance with NAFLD regarded as the hepatic 
manifestation of the metabolic syndrome [3]. NAFLD 
is often associated with obesity [4] and type 2 diabetes 
mellitus (T2DM) [5].
Whilst the pathophysiology of NAFLD is complex 
and not fully understood, postulated mechanisms 
include excessive hepatic triglyceride-induced inflam-
matory responses and generation of reactive oxygen 
species (ROS) leading to liver injury [6]. More recently, 
gut microbiota and gut-derived endotoxinaemia have 
been implicated in the development of NAFLD [7]. 
Lipopolysaccharide (LPS) is the active component of 
gut-derived endotoxins which exerts metabolic and 
inflammatory effects on the liver. A high fat diet is 
associated with intestinal dysbiosis resulting in higher 
proportion of LPS-producing bacteria in the gut and a 
2–3 fold increase in LPS concentration [8]. LPS com-
promises intestinal barrier integrity and increases gut 
permeability, facilitating translocation of endotox-
ins into the portal circulation [9, 10]. Within the liver, 
LPS activates the Toll-like receptor 4 (TLR4)-depend-
ent pathway in Kupffer cells resulting in activation of 
inflammatory pathways and impairment of insulin sign-
aling [9].
Individuals with NAFLD have increased risk of car-
diovascular events and mortality independent of con-
ventional risk factors and the metabolic syndrome [5, 
11–14]. NAFLD and atherosclerosis are chronic inflam-
matory conditions that seem to share common path-
ways (endothelial dysfunction, oxidative stress and 
inflammation).
Probiotics are non-pathogenic live micro-organisms 
beneficial for gut health with associated clinical ben-
efits such as improved lipid profile [15], reduced sys-
tolic blood pressure [15], improved insulin sensitivity 
[16], increased antioxidant activity [17] and decreased 
inflammation [18].
VSL#3® is a highly concentrated probiotic product 
which contains 8 different strains of live freeze-dried 
lactic acid bacteria (streptococcus thermophilus, bifi-
dobacterium breve, bifidobacterium longum, bifi-
dobacterium infantis, lactobacillus acidophilus, 
lactobacillus plantarum, lactobacillus paracasei and 
lactobacillus bulgaricus). VSL#3®-related studies on 
insulin resistance [19, 20], vascular inflammation [20], 
oxidative stress [21], endothelial dysfunction [19] and 
liver injury [19, 21] are limited. Nonetheless, the gut 
microbiota should be considered a potential therapeu-
tic target to treat patients with NAFLD.
Methods
The aim of this study was to examine the effects of 
VSL#3® probiotic supplementation on biomarkers of 
cardiovascular risk (insulin resistance, inflammation, 
endothelial function and oxidative stress) and biomarkers 
of liver injury in patients with NAFLD. We hypothesised 
that VSL#3® would improve these biomarkers.
Ethical approval was granted by NRES Committee 
South Central—Hampshire B [Whitefriars, Lewins Mead, 
Bristol BS1 2NT] (ref: 11/SC/0532) and written informed 
consent was obtained from all eligible patients. The study 
was conducted at the Diabetes Centre, QAH. Recruit-
ment began in May 2012 and ended in March 2014 when 
the study closed. Follow-up of the last patient was com-
pleted in January 2014.
A randomised, double blinded, placebo-controlled, 
proof-of-concept trial was undertaken. The primary 
outcome was to detect changes in biomarkers of insu-
lin resistance, oxidative stress, endothelial dysfunction, 
inflammation, and liver injury. The secondary outcome 
was to examine whether there were any relationships 
between insulin resistance, oxidative stress, endothelial 
function, inflammation and liver transaminases at base-
line in patients with NAFLD.
Patients aged 25–70  years with confirmed NAFLD 
(either biopsy proven or based on imaging), at least a 
20% risk of a cardiovascular event over the next 10 years 
(Qrisk2 score) [22] and HbA1c < 86  mmol/mol (10%) 
were recruited from Hepatology, Diabetes and Radiol-
ogy departments at Queen Alexandra Hospital (QAH); 
a community-based obesity clinic and Primary Care in 
Portsmouth, UK. Qrisk2 score was multiplied by a factor 
of 1.87 as existing cardiovascular risk calculators do not 
include NAFLD as a risk factor [14].
Those with established cardiovascular disease, decom-
pensated liver cirrhosis, allergy or intolerance to VSL#3® 
probiotic, chronic excess alcohol intake (> 24  g per day 
for men and > 16 g per day for women in the last 2 years), 
antibiotic treatment 4  weeks prior to the study and/
or more than 3 courses of antibiotic treatment over the 
preceding 6 months, solid organ or bone marrow trans-
plantation, and oral corticosteroid therapy were excluded 
from the study.
Keywords: Fatty liver, Probiotic, Biomarkers
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Patients were studied before and after a 10-week inter-
vention period with VSL#3® (Danisco Inc.) probiotic or 
placebo at a dose of 2 sachets twice a day [20, 21, 23]. 
They were randomised in a 1:1 ratio between the treat-
ment and placebo arms by a computer-generated code 
using random permuted blocks of randomly varying size. 
Investigators and patients were blinded to the interven-
tion throughout the study period. VSL#3® and placebo 
were supplied by Actial Farmaceutica, Italy directly to 
the Clinical Trials Pharmacy Service, QAH who were 
responsible for packaging boxes containing identical, 
non-identifiable sachets of VSL#3® and placebo.
Patients were fasted at least 12  h prior to their study 
visit. The day before their visit, foods high in fibre and 
starch were avoided and those on insulin therapy omit-
ted their insulin dose(s). On the day of their visit, patients 
were asked not to smoke or exercise 30 min prior. Con-
sumption of other probiotic products was prohibited 
during the study period.
At each visit, anthropometric data (weight and waist 
circumference) and blood pressure (Welch Allyn; 52,000 
series) were recorded. Venous blood samples were 
obtained to measure fasting insulin, fasting glucose, fast-
ing lipid profile (total cholesterol, HDL cholesterol, LDL 
cholesterol and triglycerides), HbA1c, fructosamine, 
liver enzymes (ALT and AST), albumin, INR, platelet 
count and high sensitivity C-reactive protein, and mark-
ers of endothelial function and oxidative stress. Lactulose 
hydrogen breath test (LHBT) and digital photoplethys-
mography were performed. A subset of patients had 
liver ultrasound using Acoustic Structure Quantification 
(ASQ) (Additional file 1).
Lactulose hydrogen breath test was undertaken to 
detect small intestinal bacterial overgrowth (SIBO). 
Breath samples were measured using a Micro meter H2 
(Micro Medical Rochester, Kent, UK). An increase in 
hydrogen concentration of more than 20 parts per mil-
lion from baseline within 90 min of the test and a second 
peak at least 15 min following the initial peak constitute a 
positive result [24].
Insulin resistance was calculated using HOMA2 (home-
ostasis model assessment) which provides HOMA-IR 
(Homeostatic Model Assessment for Insulin Resistance) 
estimates [25]. Three paired fasting venous glucose and 
insulin were taken at 5-min intervals, and their mean val-
ues were entered into the HOMA2 calculator. Inflamma-
tion was measured by high sensitivity C-reactive protein 
(hsCRP) [26] using immunonephelometry on a Siemens 
BN Prospec nephelometer at the Biochemical Sciences 
Department, St Thomas’ Hospital, London.
Endothelial function Digital photoplethysmography is 
a non-invasive technique for assessment of endothelial 
function. Measurements were obtained using a Micro 
Medical Pulse Trace (Rochester, Kent, UK). Reflective 
index (RI) readings were recorded before and after the 
administration of 400  μg sublingual glycerol trinitrate 
(GTN; an endothelium-independent vasodilator). Fol-
lowing a washout, RI readings were repeated before 
and after inhaled Salbutamol 400  μg (an endothelium-
dependent vasodilator). The mean RI readings was used 
to calculate the change in RI for GTN (∆RI-GTN) and 
Salbutamol (∆RI-Salb) thus determining endothelium-
independent and dependent vasodilator changes respec-
tively [27].
Soluble vascular cell adhesion molecule-1 (sVCAM-
1) [28] was measured using the Quantikine Human 
sVCAM-1 immunoassay kit from R&D Systems. Cyclic 
guanosine monophosphate (cGMP) [29] was analysed 
using the cGMP Immunoassay kit from R&D Systems.
Oxidative stress The glutathione ratio (GSH:GSSG) 
was assessed using the GSSG reductase/5,5′-dithio-
bis(2-nitrobenzoic acid) re-circulating method on whole 
blood described by Tietze [30] and Shaik and Mehvar 
[31] Total antioxidant capacity (TAC) was assessed using 
the cupric ion reducing antioxidant capacity—batho-
cuproinedisulfonic acid disodium salt (CUPRAC-BCS) 
assay as described by Campos [32]. Quantification of 
lipid hydroperoxides (LHP), a direct index of oxidative 
stress, was measured using a method described by Ruiz 
et  al. which involves a coupled glutathione peroxidase-
glutathione reductase reaction [33].
Liver injury The NAFLD fibrosis risk score [34] and 
FIB4 index [35] were used as predictive models of 
advanced fibrosis in patients with NAFLD. Acoustic 
Structure Quantification is a novel high definition ultra-
sonographic modality that processes spatial echopatterns 
from scanned tissues enabling measurement of fibrous 
structures that reflect the ultrasound beam [36]. Two 
Radiologists were designated to perform ASQ liver scan 
(Toshiba Aplio XG, Toshiba Imaging Systems) on a sub-
set of patients. The mode, average and standard devia-
tion of ASQ data were generated. The mode ASQ score 
(expressed as  C2m) was used to compare the degree of 
liver fat/fibrosis instead of the average and standard devi-
ation as the latter values can be affected by small vessels 
within the liver.
Statistical analysis
This was an exploratory proof-of-concept study examin-
ing the impact of VSL#3® on cardiovascular and hepatic 
markers given the absence of previous data upon which 
to undertake a power calculation.
Data were presented as mean and standard devia-
tion or median and inter-quartile range (IQR) for non-
parametric data. Independent t-test (or Mann Whitney 
U test for non-parametric data) assessed differences in 
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baseline characteristics between treatment groups. Study 
outcomes between the two treatment groups were com-
pared using independent t-test. Descriptive statistics for 
ANCOVA were presented as mean and SD. Wilcoxon 
Signed Rank test was used to establish any difference in 
fibrosis risk scores before and after treatment. Spear-
man’s correlation was used to determine possible associa-
tions between markers of cardiovascular risk and hepatic 
liver at baseline.
Statistical software IBM SPSS Statistics 22.0 for win-
dows (IBM Corporation 2013) was used for all analyses 
and all tests were performed at a 5% level of significance.
Results
Figure  1 summaries patient recruitment. Forty-two 
patients participated in the study but only 35 completed. 
One patient was withdrawn as he was due to undergo 
bariatric surgery whilst 6 patients withdrew from the 
study for various reasons (taste of product, personal rea-
sons, recurrent infections, nausea or diarrhoea).
Out of the 35 patients who completed the study, most 
were men (28 males and 7 females) with a mean age of 
57 ± 8  years and a relatively short duration of NAFLD 
(median duration since diagnosis of 0.3 IQR 2.0  years). 
T2DM or impaired fasting glucose was present in 74%. 
Most of the patients were obese with a mean of BMI 
32.6 ± 5.0  kg/m2 and a mean waist circumference of 
111.8 ± 12.6  cm (mean for men was 110.9 ± 11.4  cm 
and women was 115.3 ± 17.3  cm). Baseline mean blood 
pressure was 134/82 ± 13/7  mmHg, total cholesterol 
4.42 ± 1.15  mmol/l, HDL 1.06 ± 0.29  mmol/l, LDL 
2.43 ± 1.06  mmol/l, triglycerides 2.00 ± 0.88  mmol/l and 
HbA1c 53 ± 14 mmol/mol.
Baseline characteristics were similar between the two 
treatment groups (Table 1) except HOMA-IR which was 
significantly lower in the VSL#3®-treated group (1.6 IQR 
1.7 v placebo 3.0 IQR 1.8; p = 0.04). This difference per-
sisted despite the exclusion of patients on insulin.
SIBO was present in 6 out of 35 patients (17%). No 
significant differences were observed in metabolic 
parameters and markers of insulin resistance, endothe-
lial function, oxidative stress, inflammation and liver 
transaminases (ALT and AST) with VSL#3® supplemen-
tation or placebo (Tables  2, 3). Even after exclusion of 
patients on insulin therapy, there was no significant dif-
ference in insulin resistance between the two treatment 
groups. Lipid hydroperoxide was excluded from analysis 
as levels were undetectable in all but one subject.
There was no significant change in NAFLD fibrosis 
risk score or FIB4-index following VSL#3® treatment 
Assessed eligibility
n = 66
Withdrawn, unable to 
obtain blood sample (n=1)
Excluded (n=17), not meeting criteria
Declined to participate (n=5)
Withdrawn due to previous history of 






- Due bariatric surgery (n=1)
- Other reasons (taste of products,  
personal reasons, recurrent 








Ongoing acute medical issues, not 
screened (n=3)
Fig. 1 Patient recruitment
Table 1 Comparison of baseline characteristics between 
treatment groups
a p < 0.05
b Mann Whitney U test for non-parametric data one missing value on LDL as 
triglyceride (> 4.5 mmol/l) was too high for LDL calculation




placebo (n = 16)
p value




Duration NAFLD (y)b 0.25 IQR 2.0 1.0 IQR 1.5 0.27
No. of T2DM (or IFG)b 15 11 0.61
No. of  smokersb 2 2 0.94
Alcohol (units/wk)b 1 IQR 8 6 IQR 8 0.10
BMI (kg/m2)b 31.2 IQR 9.1 31.9 IQR 4.0 0.57
Waist circumference 
(cm)
112.2 ± 14.3 111.2 ± 10.7 0.81
Systolic BP (mmHg) 133 ± 13 135 ± 12 0.56
Diastolic BP (mmHg) 82 ± 8 82 ± 7 0.91
Total cholesterol 
(mmol/l)
4.51 ± 1.38 4.31 ± 0.85 0.61
HDL (mmol/l)b 0.98 IQR 0.35 0.95 IQR 0.54 0.66
LDL (mmo/l) 2.58 ± 1.18 2.42 ± 0.70 0.64
Triglycerides 
(mmol/l)b
1.80 IQR 0.45 1.80 IQR 1.27 0.73
HbA1c (mmol/mol)b 54 IQR 17 47 IQR 19 0.23
HOMA-IRb 1.6 IQR 1.7 3.0 IQR 1.8 0.04a
ALT (iu/L)b 43 IQR 56 51 IQR 30 0.96
AST (iu/L) 40 ± 16 40 ± 15 0.99
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(Table  4). The placebo-treated group had lower post 
intervention mode ASQ score than the VSL#3®-treated 
group (mode ASQ score 91  C2m and 99  C2m respec-
tively; p = 0.048).
Moderate correlation was observed between sVCAM-1 
and hsCRP (rho = 0.392, p = 0.01); between hsCRP and 
glutathione ratio (rho = 0.325, p = 0.04); and between 
HOMA-IR and AST (rho = 0.489, p < 0.01) at baseline. 
Figure  2 shows the correlation between HOMA-IR and 
AST. No other associations were found.
No serious adverse events were reported in the study. 
In the VSL#3®-treated group (n = 19), 3 patients devel-
oped a urinary tract infection, 2 had bloating, 2 had nau-
sea, 1 had genital thrush and 1 had perianal rash. In the 
placebo-treated group, 1 patient had diarrhoea, 1 had 
abdominal cramps, 1 had back pain and 1 had a trau-
matic toe infection.
Discussion
In this study, VSL#3® probiotic supplementation did not 
significantly improve insulin resistance, endothelial dys-
function, oxidative stress, inflammation or liver injury in 
patients with NAFLD.
Our patients with NAFLD have a higher mean base-
line sVCAM-1 (714 ng/ml, range 277–1151 ng/ml) than 
healthy volunteers (531  ng/ml, range 341–897  ng/ml) 
suggesting they have underlying endothelial dysfunc-
tion. The mean baseline hsCRP (4.0 mg/l) was suggestive 
of a cohort at high cardiovascular risk [26]. Similar lev-
els were reported in another study in which hsCRP was 
associated with a significantly higher relative risk of CVD 
in patients with NAFLD [13].
This is the first study to examine the impact of VSL#3® 
on ASQ in patients with NAFLD. ASQ has not been 
fully validated in patients with NAFLD and the thresh-
old that defines the severity of fatty infiltration has not 
been determined. Toyoda et al. reported strong correla-
tion between ASQ data and grades of liver fibrosis in 148 
patients with histologically proven chronic hepatitis C 
[36]. The median values of mode ASQ  (C2m) of patients 
in the study suggest that majority of them did not have 
significant fibrosis [placebo group: median value of mode 
 C2m was 101.0 (range 77.0–114.0) before treatment and 
93.0 (83.0–123.0) after treatment; VSL#3® group: 89.0 
(73.0–110.0) before treatment and 96.0 (72.0–115.0) after 
treatment].
The majority of our patients did not have pre-existing 
liver biopsy to correlate ASQ data, hence it was not pos-
sible to quantify the severity of hepatic steatosis. Focal 
disturbance ratio (a statistical model on ASQ) can quan-
tify liver fat in patients with NAFLD [37], however this 
analysis was not possible retrospectively as it required a 
different software version.
Several factors may have contributed to the lack of 
demonstrable effects of VSL#3® in our cohort with 
NAFLD. These include a relatively small sample, and the 
absence of age and sex-matched controls to determine 
whether our cohort was at high cardiovascular risk. The 
difference in baseline insulin resistance between the two 
treatment groups despite randomisation may be partly 
due to the sample size.
Studies on VSL#3® in patients with NAFLD are limited 
with the majority assessing liver-related endpoints in cir-
rhotic patients. Improvement in insulin sensitivity and 
metabolic parameters, and reduction in inflammation 
were demonstrated with 1 capsule of VSL#3® (112.5 bil-
lion bacteria) per day over 6 weeks in overweight/obese 
Indian patients [20]. Reduction in markers of oxidative 
stress was observed with 3  months of 1800 billion bac-
teria daily [21]. Ultrasonographic improvement in liver 
fat was seen in children with NAFLD after 4 months of 
Table 2 Summary of results in patients on VSL#3®
VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as 
mean and standard deviation. Four cGMP values were not measurable (3 from 
placebo group and 1 from VSL#3® group). HOMA-IR missing 1 value from each 
treatment group as insulin levels were outside the HOMA calculator range. 
HbA1c in the placebo group had one missing value. LDL cholesterol had missing 
data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides 
were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP 
values were missing after intervention on 1 patient in the placebo group. 
Nineteen patients had completed ASQ (10 in VSL#3® group and 11 in placebo 
group). Missing data were excluded from respective analyses
Measurements Mean pre-VSL#3® Mean post-VSL#3® p value
Systolic BP (mmHg) 133 ± 13 130 ± 11 0.53
Diastolic BP 
(mmHg)
82 ± 8 80 ± 7 0.42
Total cholesterol 
(mmol/l)
4.51 ± 1.38 4.42 ± 1.27 0.83
HDL (mmol/l) 1.07 ± 0.26 1.09 ± 0.24 0.79
LDL (mmol/l) 2.58 ± 1.18 2.56 ± 1.02 0.95
Triglycerides 
(mmol/l)
1.89 ± 0.57 1.91 ± 1.00 0.94
HbA1c (mmol/mol) 54 ± 12 55 ± 12 0.87
Fructosamine 
(μmol/l)
257 ± 44 263 ± 49 0.67
HOMA-IR 2.2 ± 1.9 2.2 ± 1.5 0.95
∆RI-GTN (%) 28 ± 6 25 ± 8 0.20
∆RI-Salb (%) 9 ± 8 8 ± 4 0.62
sVCAM-1 (ng/ml) 536 ± 305 524 ± 262 0.90
cGMP (pmol/l) 178 ± 57 159 ± 43 0.27
Blood glutathione 
ratio
22 ± 10 26 ± 13 0.21
TAC [mM Asc 
(AEAC)]
0.46 ± 0.04 0.47 ± 0.07 0.75
hsCRP (mg/l) 3.0 ± 2.5 3.9 ± 6.1 0.53
ALT (iu/l) 56 ± 31 51 ± 32 0.63
AST (iu/l) 40 ± 16 38 ± 20 0.78
Mode ASQ  (C2m) 91 ± 14 95 ± 16 0.57
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VSL#3® [38]. The dose and duration of VSL#3® vary con-
siderably (112.5 billion bacteria to 3600 billion bacteria 
per day; 6 weeks to 6 months) in reported studies [20, 21, 
23, 38, 39], and a 10-week intervention may be consid-
ered too short to achieve clinically meaningful results.
There were no measurements on changes in gut micro-
biota or endotoxin levels, which may have provided sup-
porting evidence in the pathogenesis of NAFLD should 
VSL#3® demonstrates modification of gut microbiota 
and reduction in gut-derived endotoxaemia.
Although HOMA is not validated for use in patients 
on insulin therapy, the use of HOMA-IR in such patients 
has been previously reported [40]. Re-analysis of the data 
excluding the 15% of patients on insulin therapy did not 
alter the study findings. Patients were less insulin-resist-
ant than reported (HOMA-IR: 2.6 ± 1.8; or 2.2 ± 1.3 if 
those on insulin treatment were excluded) which may be 
related to co-existing metformin use [41].
The reproducibility of digital volume pulse as measured 
by digital photoplethysmography can be affected by the 
ambient temperature, the perfusion of patients’ index 
finger, patients’ position, and sudden movements (e.g. 
a sneeze or cough) when measurements were recorded. 
Maintaining similar conditions in all patients undergoing 
Table 3 Summary of results in patients on placebo
VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo 
group and 1 from VSL#3® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the 
placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides were > 4.5 mmol/l 
which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed 
ASQ (10 in VSL#3® group and 11 in placebo group). Missing data were excluded from respective analyses
Measurements Mean pre-placebo Mean post-placebo p value
Systolic BP (mmHg) 135 ± 13 128 ± 17 0.19
Diastolic BP (mmHg) 82 ± 7 78 ± 11 0.27
Total cholesterol (mmol/l) 4.31 ± 0.85 4.50 ± 1.06 0.57
HDL (mmol/l) 1.05 ± 0.34 1.06 ± 0.35 0.96
LDL (mmol/l) 2.42 ± 0.70 2.50 ± 0.96 0.80
Triglycerides (mmol/l) 2.11 ± 1.15 2.39 ± 1.42 0.55
HbA1c (mmol/mol) 50 ± 15 51 ± 15 0.92
Fructosamine (μmol/l) 257 ± 53 266 ± 64 0.67
HOMA-IR 3.1 ± 1.8 3.0 ± 1.4 0.86
∆RI-GTN (%) 24 ± 7 23 ± 6 0.58
∆RI-Salb (%) 9 ± 6 9 ± 6 0.98
sVCAM-1 (ng/ml) 705 ± 423 722 ± 423 0.91
cGMP (pmol/l) 177 ± 46 177 ± 59 0.98
Blood glutathione ratio 20 ± 12 21 ± 9 0.65
TAC (mM Asc [AEAC]) 0.43 ± 0.06 0.44 ± 0.07 0.62
hsCRP (mg/l) 3.2 ± 5.3 2.7 ± 2.7 0.72
ALT (iu/l) 51 ± 19 49 ± 26 0.86
AST (iu/l) 40 ± 15 41 ± 17 0.90
Mode ASQ  (C2m) 99 ± 10 95 ± 13 0.44
Table 4 Effect of VSL#3® on fibrosis risk scores
n = 19
F0–F2 = absence of significant fibrosis
F3–F4 = presence of significant fibrosis
a Wilcoxon signed rank test
Number of patients pre-VSL#3® Number of patients post-VSL#3® p  valuea
F0–F2 Indeterminate F3–F4 F0–F1 Indeterminate F3–F4
NAFLD fibrosis risk 
score
1 11 7 3 9 7 0.16
FIB4 index 8 7 4 8 9 2 0.41
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digital photoplethysmography can be challenging and 
considered a limitation of the study.
The moderately positive correlation between baseline 
hsCRP and sVCAM-1 supports an association between 
endothelial dysfunction and inflammation in patients 
with NAFLD, and this has been similarly reported in 
another study [42]. Paradoxically, there was a moder-
ate positive correlation between hsCRP and blood glu-
tathione ratio. Perhaps, there is an initial upregulation 
of antioxidant mechanisms to compensate for pathologi-
cal states such as chronic inflammation and once these 
mechanisms are overwhelmed, glutathione ratio falls 
[43].
Insulin resistance and liver inflammation are known to 
be closely linked, and this has been demonstrated by the 
relationship between HOMA-IR and AST in our study. A 
similar relationship between insulin sensitivity and liver 
transaminases (AST and ALT) has been reported in the 
IRAS study [44].
The majority of VSL#3® studies are based on murine 
models and this study provides further insight into pos-
sible effects of probiotic supplementation cardiovascu-
lar risk and liver injury in patients with NAFLD. VSL#3® 
treatment has been shown to improve tight junction pro-
tein function [45] which is vital at maintaining intestinal 
epithelial barrier function and preventing translocation 
of gut-derived endotoxins. VSL#3® inhibited hepatic JNK 
and NF-κB activity suggesting that treatment improved 
hepatic insulin sensitivity and inhibited proinflammatory 
pathways [46]. VSL#3® also increased hepatic NKT cells 
which was associated with reduced TNFα expression and 
inhibition of IKK-β activity [47]. Decreased inflammatory 
mediators (TNFα, ICAM-1, RANTES and macrophage 
inflammatory protein-1α) within the liver was observed 
following treatment with VSL#3®, and resulted in histo-
logical improvement in liver inflammation and fibrosis 
[19].
Conclusion
This study does not support the hypothesis that probiot-
ics improve biomarkers of cardiovascular risk and liver 
injury in patients with NAFLD. However, a number of 
limitations in particular the small sample size and short 
duration of VSL#3® treatment may have negatively influ-
enced the study outcomes. Given modification of gut 
microbiota remains a potential therapeutic option in 
NAFLD, further studies are warranted to evaluate the 
benefits of probiotics in patients with NALFD.
CONSORT guidelines
The study adheres to the CONSORT guidelines and a 
completed CONSORT has been submitted separately.
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